Who are your competitors and where are you versus them in taking this process to the next level?
你们的竞争对手是谁?与他们相比,你们在今后的发展中处于何种地位?
NN: We get asked that fairly often. There are folks and entities that do pieces of what Berg does. They're leading companies focused on proteins or analytics, but there isn't one company we can identify or know of that has taken the biology, the omics, the clinical capability and put it all into an interrogative platform to really allow for a robust understanding of the biology to discover drugs in a different way. Also, we are allowing the data to generate hypotheses instead of hypotheses generating data, so it's a really different approach. We are fairly unique in that respect - both from a technology, but also from a commercial standpoint.
尼文·纳雷因:我们经常会被问到这个问题。也有一些人和机构在做我们正在做的事。他们是一些蛋白质和分析学上的顶尖公司,但我们目前还没有发现哪家公司把有关的生物学、组学研究和临床能力整合到一个疑问型平台上,来对人体产生坚实的理解,并以一种新的方式开发药物。另外,我们是用数据产生假设,而不是用假设产生数据,所以它是一种不同的方法。我们在这方面还是挺独特的--无论是在技术上还是商业上。
Carl, for the last few years, you and Mitch Gray have been the only investors in Berg. How come?
【人类能否在两三年内治愈癌症】相关文章:
★ Twitter会降低学生的考试成绩,那对其他人有什么影响
★ “晚婚不婚”上热搜,结婚率连跌5年,这届年轻人为啥不爱结婚了?
★ 爱就在你手中
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15